Breaking News

Financial Report: Biogen Idec 3Q

October 25, 2012

Revenues up 6% in the quarter on Avonex boost

Biogen Idec

3Q Revenues: $1.4 billion (+6%)

3Q Earnings: $398.4 million (+13%)

YTD Revenues: $4.1 billion (+10%)

YTD Earnings: $1.1 billion (+16%)

Comments: Avonex sales were $736 million (+8%). Tysabri sales were $275 million (-1%). Rituxan revenues from an unconsolidated joint business arrangement were $288 million (+8%). Global in-market sales of Tysabri were $404 million (+3%), including $230 million in the U.S. Revenues from other products were $28 million, compared to $17 million in 3Q11. Royalty revenues were $47 million, compared to $52 million in 3Q11. In the quarter quarter, Biogen recognized a gain of $32 million related to the sale of rights related to Benlysta.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks